Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes (MetCAB): A double-blind, randomised controlled trial

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 8, 2015, Pages 615-623

  El Messaoudi, Saloua ^a   Nederlof, Rianne ^b   Zuurbier, Coert J ^b   van Swieten, Henry A ^a   Pickkers, Peter ^a   Noyez, Luc ^a   Dieker, Hendrik Jan ^a   Coenen, Marieke J ^a   Donders, A Rogier T ^a   Vos, Annemieke ^a   Rongen, Gerard A ^a   Riksen, Niels P ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CREATININE; GLUCOSE; HEXOKINASE; HEXOKINASE 2; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INOTROPIC AGENT; INSULIN; LACTIC ACID; METFORMIN; PLACEBO; PROTEIN KINASE B; TROPONIN I; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; DIABETES MELLITUS; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; ENZYME PHOSPHORYLATION; EXTUBATION; FEMALE; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HEART MUSCLE INJURY; HOMEOSTASIS MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HUMAN TISSUE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; NETHERLANDS; POSTOPERATIVE HEMORRHAGE; PREMEDICATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; WESTERN BLOTTING; ADVERSE EFFECTS; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECTS; HEART; HEART INJURIES; INTRAOPERATIVE COMPLICATIONS; MIDDLE AGED; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; CORONARY ARTERY BYPASS; DOUBLE-BLIND METHOD; FEMALE; HEART; HEART INJURIES; HUMANS; HYPOGLYCEMIC AGENTS; INTRAOPERATIVE COMPLICATIONS; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84938212697     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00121-7     Document Type: Article

References (30)

1. Sipahi I, Akay MH, Dagdelen S, Blitz A, Alhan C Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. JAMA Intern Med 2014, 174:223-230.
2. Lurati Buse GA, Bolliger D, Seeberger E, et al. Troponin T and B-type natriuretic peptide after on-pump cardiac surgery: prognostic impact on 12-month mortality and major cardiac events after adjustment for postoperative complications. Circulation 2014, 130:948-957.
3. Domanski MJ, Mahaffey K, Hasselblad V, et al. Association of myocardial enzyme elevation and survival following coronary artery bypass graft surgery. JAMA 2011, 305:585-591.
4. Heusch G Cardioprotection: chances and challenges of its translation to the clinic. Lancet 2013, 381:166-175.
5. El Messaoudi S, Rongen GA, de Boer RA, Riksen NP The cardioprotective effects of metformin. Curr Opin Lipidol 2011, 22:445-453.
6. Whittington HJ, Hall AR, McLaughlin CP, Hausenloy DJ, Yellon DM, Mocanu MM Chronic metformin associated cardioprotection against infarction: not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013, 27:5-16.
7. Calvert JW, Gundewar S, Jha S, et al. Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes 2008, 57:696-705.
8. Bhamra GS, Hausenloy DJ, Davidson SM, et al. Metformin protects the ischemic heart by the Akt-mediated inhibition of mitochondrial permeability transition pore opening. Basic Res Cardiol 2008, 103:274-284.
9. Paiva M, Riksen NP, Davidson SM, et al. Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol 2009, 53:373-378.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352:854-865.
11. Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013, 36:1304-1311.
12. Aldam P, Levy N, Hall GM Perioperative management of diabetic patients: new controversies. Br J Anaesth 2014, 113:906-909.
13. Duncan AI, Koch CG, Xu M, et al. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth Analg 2007, 104:42-50.
14. Riksen NP, Franke B, Oyen WJ, et al. Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. Eur Heart J 2007, 28:1085-1091.
15. Wallace TM, Levy JC, Matthews DR Use and abuse of HOMA modeling. Diabetes Care 2004, 27:1487-1495.
16. Speechly-Dick ME1, Grover GJ, Yellon DM Does ischemic preconditioning in the human involve protein kinase C and the ATP-dependent K+ channel? Studies of contractile function after simulated ischemia in an atrial in vitro model. Circ Res 1995, 77:1030-1035.
17. Hausenloy DJ, Mwamure PK, Venugopal V, et al. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. Lancet 2007, 370:575-579.
18. Lexis CP, Wieringa WG, Hiemstra B, et al. Chronic metformin treatment is associated with reduced myocardial infarct size in diabetic patients with ST-segment elevation myocardial infarction. Cardiovasc Drugs Ther 2014, 28:163-171.
19. Li J, Xu JP, Zhao XZ, Sun XJ, Xu ZW, Song SJ Protective effect of metformin on myocardial injury in metabolic syndrome patients following percutaneous coronary intervention. Cardiology 2014, 127:133-139.
20. El Messaoudi S, Schreuder TH, Kengen RD, et al. Impact of metformin on endothelial ischemia-reperfusion injury in humans in vivo: a prospective randomized open, blinded-endpoint study. PLoS One 2014, 9:e96062.
21. Preiss D, Lloyd SM, Ford I, et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol 2014, 2:116-124.
22. Lexis CP, van der Horst IC, Lipsic E, et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. JAMA 2014, 311:1526-1535.
23. Ferdinandy P, Hausenloy DJ, Heusch G, Baxter GF, Schulz R Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Pharmacol Rev 2014, 66:1142-1174.
24. Whittington HJ, Babu GG, Mocanu MM, Yellon DM, Hausenloy DJ The diabetic heart: too sweet for its own good?. Cardiol Res Pract 2012, 2012:845698.
25. van den Munckhof I, Riksen N, Seeger JP, et al. Aging attenuates the protective effect of ischemic preconditioning against endothelial ischemia-reperfusion injury in humans. Am J Physiolog Heart Circ Physiol 2013, 304:H1727-H1732.
26. Nederlof R, Eerbeek O, Hollmann MW, Southworth R, Zuurbier CJ Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart. Br J Pharmacol 2014, 171:2067-2079.
27. Skyschally A, van Caster P, Boengler K, et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009, 104:15-18.
28. Anderson JL, Habashi J, Carlquist JF, et al. A common variant of the AMPD1 gene predicts improved cardiovascular survival in patients with coronary artery disease. J Am Coll Cardiol 2000, 36:1248-1252.
29. Scale T, Harvey JN Diabetes, metformin and lactic acidosis. Clin Endocrinol 2011, 74:191-196.
30. Venugopal V, Laing CM, Ludman A, Yellon DM, Hausenloy D Effect of remote ischemic preconditioning on acute kidney injury in nondiabetic patients undergoing coronary artery bypass graft surgery: a secondary analysis of 2 small randomized trials. Am J Kidney Dis 2010, 56:1043-1049.